An advisory panel for the Food and Drug Administration concluded Wednesday that Switzerland.-based Novartis AG’s version of Amgen’s arthritis drug Enbrel should be approved, according to Reuters. The ...
A state board in Colorado is working to make history by becoming the first in the country to cap the price of a drug it deems unaffordable. Amid an aggressive industry lobbying campaign, Colorado ...
Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results